Cargando…
Rosuvastatin Attenuates Myocardial Ischemia-Reperfusion Injury via Upregulating miR-17-3p-Mediated Autophagy
Myocardial diseases usually appear ischemic. Reperfusion therapy is one of the effective methods that can improve clinical therapeutic efficacy. However, reperfusion results in myocardial injury named I/R injury. Rosuvastatin (RS) is HMG-CoA reductase inhibitor. We investigated the role of RS in the...
Autores principales: | Wang, Xiaoqin, Chen, Jinghan, Huang, Xiaojiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918854/ https://www.ncbi.nlm.nih.gov/pubmed/31730378 http://dx.doi.org/10.1089/cell.2018.0053 |
Ejemplares similares
-
Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting complement activation and upregulation of miR-499
por: Huang, Zheng, et al.
Publicado: (2021) -
Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR-γ and UCP2
por: Wang, Ling, et al.
Publicado: (2018) -
miR-129 Attenuates Myocardial Ischemia Reperfusion Injury by Regulating the Expression of PTEN in Rats
por: Dai, Zhao-Hui, et al.
Publicado: (2021) -
miR-17-5p attenuates kidney ischemia-reperfusion injury by inhibiting the PTEN and BIM pathways
por: Ma, Ming, et al.
Publicado: (2021) -
miR-125a, miR-139 and miR-324 contribute to Urocortin protection against myocardial ischemia-reperfusion injury
por: Díaz, Ignacio, et al.
Publicado: (2017)